Impact of Cabozantinib Exposure on Proteinuria and Muscle Toxicity in Patients with Unresectable Hepatocellular Carcinoma.

Okubo, Hironao; Ando, Hitoshi; Takasaki, Yusuke; Nakadera, Eisuke; Fukuo, Yuka; Shiina, Shuichiro; Ikejima, Kenichi

Okubo, Hironao; Ando, Hitoshi; Takasaki, Yusuke; Nakadera, Eisuke; Fukuo, Yuka; Shiina, Shuichiro; Ikejima, Kenichi.

Afiliação

Okubo H; Department of Gastroenterology, Juntendo University Nerima Hospital, Tokyo 177-8521, Japan.
Ando H; Department of Cellular and Molecular Function Analysis, Kanazawa University Graduate School of Medical Sciences, Kanazawa 920-8640, Japan.
Takasaki Y; Department of Gastroenterology, Juntendo University Nerima Hospital, Tokyo 177-8521, Japan.
Nakadera E; Department of Gastroenterology, Juntendo University Nerima Hospital, Tokyo 177-8521, Japan.
Fukuo Y; Department of Gastroenterology, Juntendo University Nerima Hospital, Tokyo 177-8521, Japan.
Shiina S; Department of Gastroenterology, Juntendo University School of Medicine, Tokyo 113-0034, Japan.
Ikejima K; Department of Gastroenterology, Juntendo University School of Medicine, Tokyo 113-0034, Japan.

Pharmaceuticals (Basel) ; 15(12)2022 Nov 25.

Article em En | MEDLINE | ID: mdl-36558911

Palavras-chave

cabozantinib; hepatocellular carcinoma; muscle enzyme; pharmacokinetic analysis

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google